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IMPORTANCE OF INITIAL MANAGEMENT OF PERSONS
INTERNALLY CONTAMINATED WITH RADIONUCLIDES
The first one or two hoursaftereradiation ace
radionuclide has been inhaled, ingested, or injected; may^  be the crucial time
for effective treatment. First aid following internal contamination, just
like first aid following a traumatic injury, may determine the prospects for
success in a total treatment program. If no action is taken by plant health
personnel and referral has to be made to a distant medical center, many hours
may be lost and a golden opportunity missed.
Following internal contamination there is usually a period of time before
the radionuclide has been absorbed, transported and taken up by tissue cells.
The absorption from the lung, gut, or wound, can sometimes be reduced by chem-
ical manipulation in the GI tract, or by hastening the passage of the material
through the body. Alkalizing the stomach may cause the formation of relatively
insoluble hydroxides or will at least keep the pH high enough to reduce solu-
2 3bility of some metal salts. Metals such as copper, iron, or plutonium are
generally more available for later absorption after spending some time in the
acid milieu of the stomach. With chromium, the opposite is true. Acid gas-
4
trie juice reduces hexavalent chromium to the poorly absorbed trivalent ion.
The administration of a cathartic such as magnesium sulfate will shorten the in-
testinal transit time, thereby reducing absorption and radiation exposure to
the gut wall and nearby tissues. Once absorbed, uptake can be reduced by the
use of blocking agents, isotopic dilution, or chelating agents.
Research sponsored by the Energy Research & Development Administration
imder contract with the Union Carbide Corporation.
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A blocking agent is a chemical which saturates a tissue with a non-
radioactive element, thereby reducing the uptake of the radionuclide. Isotopic
dilution refers to the administration of large quantities of the stable iso-
tope of the radionuclide so that on a statistical basis alone, the opportunity
for incorporation of atoms of the radionuclide is lessened. With isotopic dilu-
tion, it is desirable to get the stable isotope into the system quickly, and
when possible, in a chemical form that is more easily absorbed and incorporated
than the radioisotope. A special form of dilution therapy, sometimes called
displacement therapy, refers to the use of a non-radioactive element of a dif-
ferent atomic number to compete with the radionuclide. An example would be the
use of calcium to compete with radiostrontium or stable iodine to reduce the
thyroidal uptake of radiotechnetium. ehelating agents bind metals into com-
plexes, preventing tissue uptake and allowing urinary excretion.
Highly selective uptake of any radionuclide, for example I, into the
239thyroid gland or Pu into the bone and liver, should be avoided if possible.
Accidental inhalations or injections of I may occur following a nuclear
reactor accident since it is a prominent early fission product, or during the
manufacture or misadministration of the radiopharmaceutical. Inhaled iodine
reaches equilibrium with body fluids in about 1/2 hour and approximately 30
percent of the uptake is deposited in the thyroid. One hundred mg of stable
iodine, if given within two hours or less after exposure, will reduce the up-
take by the thyroid gland by about 90 percent. Stable iodine given as late
as six hours after exposure will reduce uptake by about 50 percent and begun
as late as 24 hours will shorten the biological half-life.
If given promptly, diethylenetriaminepentaacetic acid (DTPA) will greatly
239 6
reduce the uptake of absorbed Pu into the skeleton. Smith has shown that
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in pigsf whose metabolism of Pu is similar to humans, the skeletal retention
of plutonium was reduced by a factor of 10 over controls as a consequence of
239
DTPA treatment one hour following injection of 25 uCi of Pu citrate. Eighty-
three percent of the plutonium was harmlessly excreted in the urine.
The uptake of some of the actinides is remarkably rapid. One hour after
injection of soluble 241Am or 242Cm only three to ten percent of the dose was
still circulating anddeposition in bone was 76 percent complete. DTPA, to
be maximally effective, has to be administered within the first 15-45 minutes
after inhalation or injection of a soluble actinide compound.
Once uptake of a radionuclide has occurred, there is often little one can
do but patiently wait for metabolism and excretion as well as physical decay
to occur. Chelating agents such as EDTA, DTPA, BAL, penicillamine, or deferox-
amine are sometimes useful after uptake has occurred, but their effectiveness
is greatly reduced.
Table 1 below contains a list of some commonly used radionuclides and
medications useful in preventing their uptake. The reported effectiveness of
the treatment is also included when known. In addition to these medications,
there may be other chemical or dietary manipulations which could be useful.
A list of a few possibilities appears in Table 2. The agents in Table 1 or
2 must be administered by a physician familiar with possible contraindications
or adverse reactions. With further study, effectiveness and safety of the
agents in Table 2 could be determined in animal systems and their possible
application to human accident cases could be determined.
In the management of internal contamination, medical action, even though
of only modest effectiveness, has an additional psychotlierapeutic effect. The
physician who knows something about the absorption and metabolism of a
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radionuclide and is able to prescribe a prompt course of action inspires con-
fidence. If he seems helpless and covers his ignorance by vague reassurements,
he may only increase anxiety. His therapy, of course, must do no harm and
should have some reasonable promise of benefit.
....
In reviewing both Tables 1 and 2, the need for preplanning in an accident
should be obvious. In order to administer any of these agents, they must be
immediately available. In locations where only a small number of radibriuclides
are used, there should be no problem in stocking an appropriate supply in the
medical department or pharmacy. In research laboratories and hospitals, where
a wide variety of radionuclides may be used, keeping all possibly useful items
on hand may be difficult. Regardless, careful preplanning should lead to
better preparedness. Too few users of radionuclides think an accident will
ever happen. If and when it does, however, they will expect the occupational
medical department to be completely prepared.
SUMMARY
The first one to three hours following a radiation accident during which
internal contamination occurs provide the best and perhaps the only opportunity
for preventing uptake of radionuclides. By using chemical manipulation in the
GI tract or by hastening the material through the body, absorption can be re-
duced. Once absorbed, uptake in specific tissues can often be prevented by
blocking agents, isotopic dilution or chelating agents. In order to supply
prompt treatment, the medical department must have a well-defined action plan
based on knowledge of the plant or laboratory operations, the radionuclides
used, and medications required.
Table 1
MEDICATIONS USEFUL IN PREVENTING UPTAKE OF RADIONUCLIDES
RADIONUCLIDE
241A»,
252cf
144Ce and
Bare Earths
to Lutetian
137Cs
ROUTE OF EOTR1T
Inhalation **
Injection
Inhalation
Ingestion
Injection
Inhalation
Ingestion
Injection
Inhalation
Ingestion
MEDICATION
OTFA
DTPA
DTPA
Prussian Blue***
;Bio-Rex 40®
DOSE
1 gm IV in 250 ml
isotonic saline or
5% dextrose in
water.
May also be aiven
as aerosol.,
1 GM IV in 250 ml
isotonic saline or
5% dextrose in
water. :
May also be given
as aerosol.*-"
1 gm IV in 250 ml
isotonic saline or
5% dextrose in
water.
May also be given
as aerosol.10
Irrigate wound
with 1 gm solu-
tion as needed.
1 gm initially.
.5 gm at 4 hrs &
.5 gm at 8 hrs.
Not determined
yet for humans.
EFFECTIVENESS
In humans, 50% of body burden
removed, even when therapy
long delayed. In rats, DTPA
l.day after administration of
Am reduced bone content to
50% of control value.
Early aerosol chelation with
DTPA of estimated 20-30 nCi and
catharsis with Fleet's Phospo-
Soda ® reduced uptake to below
detectable level in 75 days.
When rare earths promptly com-
plexed with DTPA they are al-
most entirely excreted.
If given within 10 minutes.
•reduces absorption from gut
by 40%.
As effective as Prussian Blue
in rats. Resin should be non-
toxic in humans since insoluble
in water and dilute HC1.
COMMENTS
Ref. 6,9
Ref. 11
Ref. 12
Ref. 13
Ref. 14
*Oral administration unless otherwise indicated.
"Inhalation of soluble or insoluble materials has ah ingestion component due to mucociliary clearance.
***Not absorbed from gut. Acts as exchange resin. May be made by mixing 0.5 molar solutions of F e d 3 and K.[Fe(CN),]
solutions in the ratio 4:3, removing KC1 by washing precipitate. See Reference 13.
Table 1 (Cont'd)
Medications Useful in Preventing Uptake of Radionuclides
• > « - %
RADIONUCLIDE
242Q»
3H
1 3 1I
140La
210Pb
ROUTE OF ENTRY
Inhalation
Inhalation
Ingestion
Injection
Inhalation
Ingestion
Injection
Inhalation
Injection
Inhalation
Ingestion
Injection
MEDICATION
DTPA
Water
Potassium iodide
(iugol's Solution)
DTPA
Calcium disodiura
EDTA
(Versenate®,Riker)
Penicillamine
(Cuprimine®,Merck,
Sharp s Dohme)
DOSE
1 gm IV in 250 ml
isotonic saline or
5% dextrose in
water. ; • • !.: •
May also be given
as aerosol.i"
1-2 liters initi-
ally, continue to
force fluids (5-
10 liters/day)for
7-14 days.
12.8 liters per
day.
100 mg
2-3 drops in
glass of water.
1 gm IV in 250 ml
isotonic saline or
5% dextrose in
w a t e r . \ , • ;; !•
May also be given
as aerosol .J0
1 gm IV in 250-506^
ml isotonic saline"
or 5% dextrose in
water.
See directions on
pkg. 500 mg/24 hrs.
Give on empty sto-
mach.
EFFECTIVENESS
Appeared to have prevented
uptake following inhalation
exposure.
Beneficial when given prompt-
ly. Not effective after fixed
in tissue.
3H rapidly incorporated into
body water. Isotopic dilution.
Excretion of 3H can be in-
creased 10-20 times by prompt
treatment.
Half-time of body water re-
duced from 11.5 days to 2.4
days.
Reduces uptake by thyroid by
90% if given within 2 hours.
10 times more effective than
EDTA. If given immediately |
might increase excretion from! ;
< 2 % i - , t o ^ 6 0 % /""" •""••••'• '•••"--'«'f"vr,'r •
•t'ltmis;:i.emu. ,•;•• :?ij.!.--.!-- • i < «
Principal use in nonradioactive
lead poisoning.
COMMENTS
Ref. 15
Ref. 16
Hef. 17
Ref. 18
Bef.5,19
Ref. 20
Ref. 21
Ref. 22
0V
Table 1 (Cont'd)
Medications Useful in Preventing uptake of Rsdionuclides
RADIOHUCLIDE
203Hg
32P
239Pu,
2 3 8P«
2l
°Po
1 4 3P»
a6Rb
ROUTE OF ENTRY
Ingestion
Injection
Inhalation
Ingestion
Inhalation
Inhalation
Ingestion
Injection
Injection
Inhalation
Ingestion
MEDICATION
Penicillamine
\ \ (Cupriinine®,Mexck,
Sharp G Dohme)
;[ Phosphorus
(Neutraphos®,
Willen)
DTPA
Dimercaprol
(BAL>
DTPA
Chlbrthalidone
(Hygroton®, U.S.V.)
DOSE
See directions on
pktf. 500 mg/24
hrs. Give on
empty stomach.
2 capsules in
glass water.
1 gin IV in 250 ml
isotonic saline or
5% dextrose in
water.
May also be given
as aerosol.1°
2.S rogAg IM 4
tines a day for 2
days;2 tines/day
on 3rd day, then
once daily I for 10
days as needed.
1 gm IV in 250 ml
isotonic saline or
5% dextrose in
water.
May also be given
as aerosol.10
50 mg orally per
•day.| "'''::' :
EFFECTIVENESS
Reported for rats only. Half-
times of both components of
excretion curves significantly
shortened by 50 mg dose.
Isotopic dilution. 4 capsules
supply 1 gm of phosphorus.
Reduced uptake by factor of 10
when given in first hour.
Dose rate to spleen in rats from
oxathiol, a closely related com-
pound, was 6.5-11.6* of dose-
rate in untreated animals.
When DTPA given within 30 min-
utes, body content reduced to
14% control/ "" ' -.-'«vfrf;""fi
More than doubled excretion.
COMMENTS
Ref.22
Ref. 6
Ref.23
Ref.24
Ref. 25
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Table 1 (Cont'd)
Medications Useful in Preventing Uptake of RacUonuclidea
RADIONUCLIDE
46SC
85sr.89sr.
99
 Tc
90y
ROUTE OF ENTRY
Inhalation
Injection
Inhalation
Ingestion
Ingestion
Inhalation
Ingestion
Inhalation
Ingestion
Inhalations
Inhalation
Ingestion
Injection
Inhalation
Injection
MEDICATION
DTPA
Sodium alginate
(Gaviscon®, Marion
Labs)
Aluminum phosphate
gel! (Fhosphajel®,
Wyeth)
Aluminum hydroxide
lAmphojel® Susp..
Hyeth)
• [ •
Calcium carbonate
Potassium iodide
(Lugol's solu-
tion
t/TPA
DOSE
1 go IV in 250 ml isotonic
saline or 5% dextrose in
'water. ?• ••' : ;•, '
May also be given as
aerosol.10
10 grams
1.5 gn
Chew 5-10 tabs stat,
2-4 every 2-4 hrs for
24 hours.
100 ml stat
40 ml every 1-2 hrs
depending on route of
-entry.' '•• •< ''•
65 ml stat. ;
40 ml every 1-2 hours
depending on route of
entry.- :
Chew 2, 600-mg tabs
every hour depending
on route of entry.
100 ng
2-3 drops in glasa of
water. ' • H^'l;-
1 gm IV in 250 ml isotonic
saline or 5% dextrose in
water./
Hay also be given as
aerosol.«
EFFECTIVENESS
Increases urinary axcretion
20-30 times
Decreases absorption from gut
by a factor of 8-10
'Decreases absorption from gut
by a faccor of 2.
Not reported. Dose based on
extrapolation from sodium al-
ginate experience. See
references.
Reduces absorption from gut
;;by,!87%;'':---'""—r" •"*
Reduces=absorption from gut
by 50% ""• ""- -
Less ezrective than otner
''methods i!:'"' ""'""" "'"""
Reduces uptake by thyroid.
Increases urinary excretion
from .5% in 24 hrs to 48*
in 24 hours. ;
COKHEHTS
Ref. 26
Ref. 27,28
Ref. 29
Ref. 30
Ref. 31
Table 1 (Cont'd)
Medications Useful in Preventing Uptake of Radionuclictes
RADIONUCLIDE
65an
ROUTE OF ENTRY
Inhalation
Ingestion
Injection
MEDICATION
DTPA
DOSE
1 qm IV in 250 ml iso-
tonic saline or 5% dex-
trose in water.
Hay also be given as
aerosol.10
EFFECTIVENESS
Increases urinary excretion
30 tines ovee non-treated.
COMMENTS
Ref. 31
Table 2
MANIPULATIONS POSSIBLY USEFUL IN PREVENTING
UPTAKE OF RADIONUCLIDES
RADIONUO.IDE
51Cr
6 0Co
6 4Cu
59Pe
"HO
ROUTE OF ENTRY
Inhalation
Ingestion
Inhalation
Ingestion
Injection
Inhalation
Ingestion
Injection
Ingestion
Inhalation
Inhalation I
Ingestion
Injection
MEDICATION OR
DIETARY MANIPULATION
Avoid antacid.
Vitamin B-12
CaCO3 and FeS
Zinc and molybdenum
Raise pH of stomach with vigor-
ous antacid therapy , j
Phytates
DTPA r !
Deferoxamine mesylate
Eggs
Ascorbic;acid
MgSO4 or Ha,SO4
Cabbage rich in sulfate
MECHANISM
Hexavalent chromium is better
absorbed than trivalent Cr.
Gastric acid reduces hexavalent
Cr to trivalent Cr.
Isotopic dilution.
Increases pH in stomach and
forms CuS which is not absorbed.
Depresses copper absorption.
Inorganic Fe forms complexes with
normal gastric juice at low pH
Which remain soluble in higher pH
of duodenum where iron absorbed.
Reduce absorption.
Chelating agent.
Chelating agent.
Decrease absorption. Yolk causes
protein binding and reduced ab-
sorption.
Increases absorption - should be
avoided.
Sulfate limits retention by re-
ducing absorption and increasing
urinary excretion.
COMMENTS
Ref. 4
-.•<-. . i ^
Ref. 32
Ref. 33
Ref. 3
Ref. 34
Ref. 35
Ref. 36
Ref. 37
Ref. 38
Table 2 (Cont'd)
Manipulations Possibly Useful in Preventing
Uptake of Radionuclides
RADIONUCUDE
75Se
65zn
ROUTE OP ENTRY
Injection
Ingestion
Inhalation
Ingestion
Injection
MEDICATION OR
DIETARY MANIPULATION
2% sodium sulfato in diet
Copper interferes with
zinc uptake.
Phytates reduce uptake.
MECHANISM
Increases Se excretion
threefold.
Proven in animals.
Proven in animals.
COMMENTS
Ref. 39
Ref. 40
Ref. 41
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